TY - JOUR
T1 - Establishment of KEIOi005-A iPSC line from urine-derived cells (UDCs) of a mild Alzheimer's disease (AD) donor with multiple risk SNPs for sporadic Alzheimer's disease (sAD)
AU - Supakul, Sopak
AU - Leventoux, Nicolas
AU - Tabuchi, Hajime
AU - Mimura, Masaru
AU - Ito, Daisuke
AU - Maeda, Sumihiro
AU - Okano, Hideyuki
N1 - Funding Information:
The urine sample of KEIOi005-A was primarily collected from the memory clinic of Keio University Hospital. We thank Ayaka Morimoto, Natsumi Suzuki, and Azusa Osumi for the clinical assistance and patient recruitment. This research project was supported by the Grants-in-Aid for Scientific Research (KAKENHI, #21J21244 to SS and #21K06376 to SM), the Keio Global Research Institute from Keio University (to SM and HO), the Japan Agency for Medical Research and Development (AMED) [The Acceleration Program for Intractable Disease Research Utilizing Disease-specific iPS Cells to SM and HO (JP21bm0804003)] [Cyclic Innovation for Clinical Empowerment to DI, HT, MM, SM, and HO (JP17pc0101006)], and the Keio University Doctorate Student Grant-in-Aid Program from Ushioda Memorial Fund 2021 (to SS). The graphical support was provided by Ronnakrit Rojyindeelert (Experience Designer, Science Museum of Minnesota, United States). SS is DC1 research fellow of the Japan Society for the Promotion of Science (JSPS), scholar of Otsuka Toshimi Scholarship Foundation (the fiscal year 2020), scholar of Koizumi Memorial Graduate School Special Scholarship of Keio University (the fiscal year 2021), and the fellow of Keio Medical Otsuka Fumon / Fusako Fellowship (the fiscal year 2021).
Funding Information:
The urine sample of KEIOi005-A was primarily collected from the memory clinic of Keio University Hospital. We thank Ayaka Morimoto, Natsumi Suzuki, and Azusa Osumi for the clinical assistance and patient recruitment. This research project was supported by the Grants-in-Aid for Scientific Research (KAKENHI, #21J21244 to SS and #21K06376 to SM), the Keio Global Research Institute from Keio University (to SM and HO), the Japan Agency for Medical Research and Development (AMED) [The Acceleration Program for Intractable Disease Research Utilizing Disease-specific iPS Cells to SM and HO (JP21bm0804003)] [Cyclic Innovation for Clinical Empowerment to DI, HT, MM, SM, and HO (JP17pc0101006)], and the Keio University Doctorate Student Grant-in-Aid Program from Ushioda Memorial Fund 2021 (to SS). The graphical support was provided by Ronnakrit Rojyindeelert (Experience Designer, Science Museum of Minnesota, United States). SS is DC1 research fellow of the Japan Society for the Promotion of Science (JSPS), scholar of Otsuka Toshimi Scholarship Foundation (the fiscal year 2020), scholar of Koizumi Memorial Graduate School Special Scholarship of Keio University (the fiscal year 2021), and the fellow of Keio Medical Otsuka Fumon / Fusako Fellowship (the fiscal year 2021).
Publisher Copyright:
© 2022 The Author(s)
PY - 2022/7
Y1 - 2022/7
N2 - Sporadic Alzheimer's disease (sAD) is a neurodegenerative disease that has the highest prevalence among patients with dementia. The genetic risk factors for sAD are comprised of many single nucleotide polymorphisms (SNPs), as indicated by genome-wide association studies. Herein, we generated the KEIOi005-A-induced pluripotent stem cell (iPSC) line from urine-derived cells (UDCs) of a mild Alzheimer's disease (AD) patient with multiple sAD risk SNPs comprising T > C heterozygous APOE ε3/ε4 (rs429358), A > G heterozygous BIN1 (rs744373), and T > G homozygous MS4A6A (rs610932). The established iPSC line demonstrates normal stemness and pluripotency and can be used for in vitro disease modeling of AD.
AB - Sporadic Alzheimer's disease (sAD) is a neurodegenerative disease that has the highest prevalence among patients with dementia. The genetic risk factors for sAD are comprised of many single nucleotide polymorphisms (SNPs), as indicated by genome-wide association studies. Herein, we generated the KEIOi005-A-induced pluripotent stem cell (iPSC) line from urine-derived cells (UDCs) of a mild Alzheimer's disease (AD) patient with multiple sAD risk SNPs comprising T > C heterozygous APOE ε3/ε4 (rs429358), A > G heterozygous BIN1 (rs744373), and T > G homozygous MS4A6A (rs610932). The established iPSC line demonstrates normal stemness and pluripotency and can be used for in vitro disease modeling of AD.
UR - http://www.scopus.com/inward/record.url?scp=85129797917&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129797917&partnerID=8YFLogxK
U2 - 10.1016/j.scr.2022.102802
DO - 10.1016/j.scr.2022.102802
M3 - Article
C2 - 35537244
AN - SCOPUS:85129797917
SN - 1873-5061
VL - 62
JO - Stem Cell Research
JF - Stem Cell Research
M1 - 102802
ER -